异环磷酰胺、卡铂和依托泊苷（ICE）作为二线方案单独使用以及与区域热疗联合使用，对经化疗预处理的成人晚期软组织肉瘤有效。

Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults.

作者信息

Fiegl M, Schlemmer M, Wendtner C-M, Abdel-Rahman S, Fahn W, Issels R D

机构信息

Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany.

出版信息

Int J Hyperthermia. 2004 Sep;20(6):661-70. doi: 10.1080/02656730410001714959.

DOI:10.1080/02656730410001714959

PMID:15370821

Abstract

PURPOSE

To evaluate the efficacy and safety of the combination of ICE (ifosfamide 1.5 g m(-2), carboplatin 100 mg m(-2) and etoposide 150 mg m(-2), days 1-4, q 28 days, G-CSF 5 microg kg(-1) starting from day 6) alone and in combination with regional hyperthermia (RHT) in soft tissue sarcoma (STS) refractory to previous standard doxorubicin-ifosfamide-based chemotherapy.

PATIENTS AND METHODS

Twenty patients with advanced STS of different histological sub-types were treated with the ICE regimen with 13 patients receiving additional RHT. A median of four courses of ICE were administered with RHT on days 1 and 3 (60 min, T(max) 42 degrees C).

RESULTS

The objective response rate was 20%, with four partial responses (all treated with hyperthermia). In addition, two patients showed mixed responses and five patients stable disease. After a median follow-up time of 15 months, median time to progression was 6 months. Progression free rate estimates were 60% and 45% at 3 and 6 months, respectively. Median overall survival for all patients was 14.6 months.

CONCLUSION

These results suggest that ICE alone or combined with RHT shows activity as second-line therapy in doxorubicin-ifosfamide-refractory STS.

摘要

目的

评估ICE方案（异环磷酰胺1.5 g m⁻²、卡铂100 mg m⁻²和依托泊苷150 mg m⁻²，第1 - 4天，每28天重复，从第6天开始使用粒细胞集落刺激因子5 μg kg⁻¹）单独使用及联合区域热疗（RHT）治疗既往对基于阿霉素-异环磷酰胺的标准化疗耐药的软组织肉瘤（STS）的疗效和安全性。